Four-Pronged attack tested against spreading esophageal cancer
NCT ID NCT07455019
Summary
This study is testing a combination of four treatments for a specific type of advanced esophageal cancer. It aims to see if using a new antibody drug (bemosubaiabimab) together with a cancer growth blocker (anlotinib), radiation, and chemotherapy is safe and effective. The trial will enroll 28 patients in China who have cancer that has spread to no more than five other spots in the body. After initial treatment, patients continue taking two of the drugs long-term to try to keep the cancer under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.